Novo's Wegovy and Ozempic removed from US FDA shortage list, compounders on notice
The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, a declaration that will curtail widespread sales of cheaper copies made by compounding pharmacies.
Discover how this diabetes drug is revolutionizing heart health. Learn about its surprising benefits in reducing cardiovascular risks and mortality.
An FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease may also help ...
GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings.
A federal judge in Missouri rejected three major pharmacy benefit managers’ push to pause the Federal Trade Commission’s ...
Research reveals GLP-1 and SGLT-2 medications may lower COPD exacerbation risk in diabetes, offering new hope for dual ...
The medication, known as sodium-glucose co-transporter 2 inhibitors (SGLT2is), is already used to lower blood sugar in people ...
Diabetes can be expensive to manage. Some programs can help you afford your diabetes medications, devices, and supplies. Here are some tips to help possibly lower your diabetes costs. Managing ...
Although the condition can sometimes be controlled through diet and exercise, many people need medications to manage their blood glucose levels once their cells stop responding to insulin, the ...
Birmingham is suing drug manufacturers and health companies, alleging they worked together to establish an “insulin pricing scheme” and inflate the cost of life-saving medicine. The lawsuit ...
The shortage of Novo Nordisk’s (NVO) blockbuster diabetes and weight-loss drugs is officially over, according to the U.S.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback